Results 81 to 90 of about 286,157 (290)

JAK2 46/1 (GGCC) Haplotype in Oncogenesis, as Risk Stratifier, and Indicator for Drug Resistance in Myeloproliferative Neoplasms

International Journal of Molecular Sciences
The JAK2 46/1 (“GGCC”) haplotype is an inherited genetic variation within the Jak2 gene locus that has become a focal point in research related to oncogenesis, particularly in myeloproliferative neoplasms (MPNs). We conducted a narrative review of landmark discoveries in hematological malignancies and Jak2, focusing on its role in oncogenesis, risk ...
Michela Perrone, Sara Sergio, Beatrice Pranzo, Amalia Tarantino, Giuseppina Loglisci, Rosella Matera, Davide Seripa, Michele Maffia, Nicola Di Renzo   +8 more
openaire   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms

Frontiers in Pharmacology
Leukemia represents a diverse group of hematopoietic neoplasms that can be classified into different subtypes based on the molecular aberration in the affected cell population. Identification of these molecular classification is required to identify specific targeted therapeutic approaches for each leukemic subtype.
Meike Kaehler, Nikolas von Bubnoff, Ingolf Cascorbi, Sivahari Prasad Gorantla   +3 more
openaire   +3 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia [PDF]

, 2015
Several chemo-resistance mechanisms including the Bcl-2 protein family overexpression and constitutive activation of the PI3K/Akt/mTOR signaling have been documented in acute lymphoblastic leukemia (ALL), encouraging targeted approaches to circumvent ...
ALLEGRETTI, MATTEO, Bergamo, P, FOA, Roberto, Iacovelli, S, LICCHETTA, ROBERTO, Martelli, Am, Mccubrey, Ja, Milella, M, MIRABILII, SIMONE, RICCIARDI, Maria Rosaria, Rinaldo, C, TAFURI, Agostino, Zeuner, A   +12 more
core   +1 more source

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, EarlyView.
Stephanie Juané Kennedy
wiley   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Venetoclax in the Therapeutic Strategy for BPDCN Management

eJHaem
Background Venetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials.
Margaux Poussard, Maxime Fredon, Imane Belakri, Sabeha Biichle, Florian Renosi, Evan Seffar, Morgane Boichut, Romain Boidot, Elodie Bôle‐Richard, Francis Bonnefoy, Marie Kroemer, Sophie Bonnot‐Perrin, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre   +15 more
doaj   +1 more source

Celecoxib in breast cancer prevention and therapy. [PDF]

, 2018
Breast cancer has a high incidence worldwide. The results of substantial studis reveal that inflammation plays an important role in the initiation, development, and aggressiveness of many malignancies. The use of celecoxib, a novel NSAID, is repetitively
Cao, Wei, Hao, Qiongyu, Li, Jieqing, Vadgama, Jaydutt V, Wu, Yong   +4 more
core  

Dynamics of growth factor production in monolayers of cancer cells and evolution of resistance to anticancer therapies [PDF]

, 2013
Tumor heterogeneity is well documented for many characters, including the production of growth factors, which improve tumor proliferation and promote resistance against apoptosis and against immune reaction.
Achilles, Aktipis, Aktipis, Amit, André, Archetti, Archetti, Archetti, Archetti, Archetti, Archetti, Armitage, Ashley, Axelrod, Basanta, Basanta, Basanta, Basanta, Basanta, Boza, Byrne, Cairns, Charles, Chuang, Crespi, Crespi, Dexter, Dingli, Durrett, Eungdamrong, Fisher, Foster, Frank, Gatenby, Gatenby, Gerstung, Gonzalez-Garcia, Greaves, Hanahan, Hardin, Hauert, Hemker, Ifti, Iwasa, Jouanneau, Knudson, Lambert, Maley, Marusyk, Maynard Smith, Mendes, Merlo, Motro, Nagy, Nordling, Nowell, Ohtsuki, Pacheco, Palfrey, Pepper, Perc, Rapoport, Ricard, Sugden, Tomlinson, Tomlinson, Traulsen, Traulsen   +67 more
core   +1 more source